Literature DB >> 20709771

Chronic viral hepatitis and chronic kidney disease.

Elias C Chacko1, Soondal Koomar Surrun, T P Mubarack Sani, Joseph M Pappachan.   

Abstract

Chronic kidney disease (CKD) has become a major public health problem worldwide over the past few decades because of the increasing prevalence of hypertension, diabetes mellitus, and elderly individuals in most countries. Chronic viral hepatitis (due to hepatitis B virus (HBV) and hepatitis C virus (HCV)) also poses significant morbidity and mortality globally. Both these viruses can cause CKD and these infections can occur as a consequence of CKD management. CKD patients acquiring HBV or HCV infection have higher morbidity and mortality rates, and the management of these infections among CKD patients with antiviral agents is associated with high rates of adverse effects. The optimal management of CKD associated with HBV and HCV is not well defined because of insufficient data from clinical trials. This review discusses the pathogenesis, clinical characteristics and management issues related to chronic viral hepatitis and CKD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709771     DOI: 10.1136/pgmj.2009.092775

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

1.  Immune mediated crescentic MPGN secondary to HBV infection: A rare presentation for a common infection.

Authors:  Aswani Srinivas Mareddy; Dharshan Rangaswamy; Mahesha Vankalakunti; Ravindra Prabhu Attur; Shankar Prasad Nagaraju; Neeraja Koti
Journal:  Australas Med J       Date:  2016-01-31

2.  Assessment of Liver Fibrosis by Transient Elastography Should Be Done After Hemodialysis in End Stage Renal Disease Patients with Liver Disease.

Authors:  Sunil Taneja; Amritangsu Borkakoty; Sahaj Rathi; Vivek Kumar; Ajay Duseja; Radha K Dhiman; Krishan L Gupta; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

3.  Hepatitis C infection and chronic renal diseases.

Authors:  Aline Gonzalez Vigani
Journal:  Hepatol Int       Date:  2012-03-15       Impact factor: 6.047

4.  Immune response to hepatitis B vaccine in patients with chronic kidney disease.

Authors:  Behzad Einollahi
Journal:  Hepat Mon       Date:  2011-10       Impact factor: 0.660

5.  13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan.

Authors:  Yi-Chun Chen; Yu-Chieh Su; Chung-Yi Li; Shih-Kai Hung
Journal:  BMC Nephrol       Date:  2015-07-22       Impact factor: 2.388

Review 6.  Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection.

Authors:  Young-Mo Yang; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2017-09-26       Impact factor: 2.423

7.  Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.

Authors:  Yi-Chun Chen; Chung-Yi Li; Shiang-Jiun Tsai; Yen-Chun Chen
Journal:  World J Gastroenterol       Date:  2018-02-28       Impact factor: 5.742

8.  Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis.

Authors:  Henry L Y Chan; Javed Shaikh; Subhajit Gupta; Kamal Hamed
Journal:  Adv Ther       Date:  2016-05-04       Impact factor: 3.845

9.  Association between hepatitis B virus infection and chronic kidney disease: A cross-sectional study from 3 million population aged 20 to 49 years in rural China.

Authors:  Ye Du; Shikun Zhang; Mei Hu; Qiaomei Wang; Na Liu; Haiping Shen; Yiping Zhang; Donghai Yan; Man Zhang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

10.  A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney Disease.

Authors:  Yi-Chun Chen; Shang-Jyh Hwang; Chung-Yi Li; Chia-Pin Wu; Li-Chu Lin
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.